A Landscape of Artificial Intelligence (AI) In Pharmaceutical R&D

Where you find opportunities to grow

* Can't find your brand, product, service? Join BPT Marketplace

Europital forecast 30% CAGR from UK biotech for three years

   by Abdul Khalifeh, Contributor    5888    Comments 0

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

CRO opens new Oxford site in response to urgent demand from small and medium innovators for specialist scientific expertise

Europital – the global provider of medical management services for clinical research and drug development – announces it is opening a UK site to further expand its services to the UK biotech industry. The company is already working with a number of UK partners and is forecasting compound growth nearly 30% of the next three years.

The Europital site will expand out its operational team over the next few months and will target working with small and medium biotechs to design & execute projects, particularly for First in Man, Phase I and Phase II clinical studies.

“We already partner with several biotechs in the UK and what we have seen is that there is a clear gap in the market for small innovators looking for a science focussed CRO that can provide the detailed knowledge and therapeutic experience. Gaining access to senior medical CRO expertise can be extremely challenging for the smaller innovators. What they need is a partner to bring a medical department with real-world trial experience to implement study design and protocols and be a scientific driving force behind project’s success,” commented Dr. Mohamed El Malt, CEO and Chief Medical Officer of Europital.

Europital is planning to quickly expand its offering and will focus on providing expertise to partners in complex oncology indications, inflammatory diseases, immunology & infectious diseases studies. The UK site opening will be used to leverage the company’s phase iii experience with clinical studies directly conducted at UK investigative sites.

“It’s a really exciting time for innovators in the UK and the four biotech hubs have a really vibrant pipeline of candidates. But, much of this cutting edge innovation lies with smaller companies and spin-outs that really need the help of a science-driven CRO – not a volume-driven large CRO that usually won’t give the study the attention it needs. You often hear ‘follow the molecule’ in CRO circles. What we are doing is following the innovator and looking at where we can best help partners advanced targets more quickly through clinical trials. There is a real shortage of senior experience in the market because of the number of trials underway. It is then perhaps unsurprising that we have seen almost 100% repeat business and we expect to see rapid growth in client demand. We add value to each step of their projects from study design until the conclusion. And, this development also opens up direct access to UK investigational sites for our existing European and North American partners with phase iii studies. But this latest announcement is part of wider expansion, so there will be more news to follow imminently,” added  Dr. El Malt.

 

-ENDS-

 

 

About Europital

 

Europital is a Global provider of Medical Management services during Clinical Research and Drug Development phases working for the pharmaceutical, biotechnology and medical device industries or with Governmental and Scientific Institutes.

The Europital Team delivers all your required Medical Expertise in International Clinical Studies from Study Design until the Final Clinical Study Report, including Medical Oversight, 24/7 Medical Monitoring and support to study teams, and Medical Review of documents and data. Our team also provides Full Medical Writing Services, in addition to Pharmacovigilance consultancy and Training and Development services.

With our scientific mindset, procedural approach and creative solutions, our team is dedicated to quality services with a high sense of project ownership. With our team readiness, reliability and flexibility, we are committed to the success of your project.

For more information visit www.europital.com.  

For media inquiries, please contact:

Alex Heeley or Abdul Khalifeh

De Facto Communications

T: +44 (0) 203 735 8168

E: a.heeley@defacto.co.uk / a.khalifeh@defacto.co.uk

 

 

 

Share this:              
A Landscape of Artificial Intelligence (AI) In Pharmaceutical R&D
 

Comments:

There are no comments yet. You can be the first.

Leave a Reply

Your email address will not be published. Required fields are marked *